| Name | Title | Contact Details |
|---|
Delinea is an ISO 9001:2015 certified CNC manufacturing company which specializes in 3+2 positional and 3 axis precision milling. Founded in 2019 by Vincent and Dan Krische, Delinea is based out of a 4,800 square foot facility in Loveland Colorado. Featuring state-of-the-art equipment and automated software we provide the crucial digital manufacturing service that you need in order to become top of your industry and a leader in innovation.
Hanon Systems is a global provider of automotive thermal and energy management solutions, based in Daejeon, South Korea. Founded in 1986 as Halla Climate Control Corp. through a joint venture between Ford Motor Co. and Mando Machinery Corporation, the company has grown to serve nearly all major automakers. As of 2025, it operates as a subsidiary of Hankook & Company Group, alongside its other core portfolios in tires and batteries. The company specializes in optimizing vehicle performance and occupant comfort through advanced thermal management technologies. Its product offerings include HVAC systems, thermal management components like compressors and cooling modules, and energy efficiency solutions aimed at reducing emissions and improving air quality. Hanon Systems has expanded its capabilities through strategic acquisitions, enhancing its position in the automotive industry. With over 50 facilities worldwide, the company is committed to providing electrification-ready solutions that support the shift toward sustainable mobility.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.